RGD Reference Report - Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2.

Authors: Ishikawa, T  Ikawa, T  Eura, M  Fukiage, T  Masuyama, K 
Citation: Ishikawa T, etal., Acta Otolaryngol. 1989 May-Jun;107(5-6):346-51.
RGD ID: 8662971
Pubmed: (View Article at PubMed) PMID:2787951

Peripheral blood lymphocytes drawn by leukapheresis using Haemonetics V50 were mixed and cultured with autologous or allogeneic tumour cell line to activate killer cells by tumour antigenic stimulation, and further with recombinant interleukin-2 (rIL-2). Killer cells were intra-arterially infused, as a primary therapy, in 5 patients with maxillary and one with lingual cancer (squamous cell carcinoma). Effects on reduction of primary tumour size were significantly high without any severe side effects. The effects were interpreted mainly by direct day-by-day observation of the site, findings of CT and histology. Histological findings of the tissue obtained by surgical operation performed after adoptive immunotherapy were remarkable changes, such as infiltration of lymphoid cells around the cancer nets, degeneration of cancer cells, infiltration of scavenger macrophages (giant cells) and so on. The results suggested that adoptive immunotherapy by the killer cells can be a powerful treatment to bring the cancer under control, in with combination of other therapies.

Annotation

Disease Annotations    

Objects Annotated

Genes (Rattus norvegicus)
Il2  (interleukin 2)

Genes (Mus musculus)
Il2  (interleukin 2)

Genes (Homo sapiens)
IL2  (interleukin 2)


Additional Information